System Building For Safe Medication by Wang, Hui-Po et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
10 
System Building for Safe Medication 
Hui-Po Wang, Jang-Feng Lian and Chun-Li Wang 
School of Pharmacy, College of Pharmacy, Taipei Medical University,Taiwan,  
Republic of China 
1. Introduction 
This article aims to report (1) the scientific aspects of system biology that governs the 
mechanism of xenobiotics-host interaction; (2) the beauty and the odds of xenobiotics in the 
biological system; (3) integrative risk-benefit assessment on using xenobiotics for medication 
purpose; (4) global trend of conceptual change in risk management from product-oriented 
pharmacovigilance to proactive pharmacovigilance planning for risk minimization; (5) 
summary of public information regarding to potential risk underlying co-medication of 
licensed drugs with complementary/alternative medicine (CAM), traditional Chinese 
medicine (TCM) and nutraceuticals; (6) epidemiological aspects in co-medication of licensed 
drugs with herbal medicine; and (7) opinion on system building for safe medication in 
societies where irrational medication and co-medication is prevalent.   
2. System biology  
2.1 The biological system  
The biological system is full of mechanisms in manipulating the action and the destination 
of xenobiotics, i. e. drugs and food, in the body.  Mechanisms governing the xenobiotic-host 
interaction include absorption, distribution, metabolism and excretion (ADME, Fig. 1).  
Typical examples associated with xenobiotic-host interaction are the change of drug efficacy 
due to the competition of drugs and food in intestinal absorption, the interference of drugs 
or food in the rate and the profile of metabolism, modification of drug distribution by food 
or other drugs, the change of renal clearance due to the competition of food and drugs for 
excretion transporters in the kidney, and the occurrence of drug resistance due to the 
modification of ADME process (Wishart, 2007).   
2.2 Evidence-based medicine 
The biological activity, i. e. the pharmacodynamic outcome, is used to be the major concern 
in conventional drug research and development.  Pharmacokinetic (PK) evaluation, the 
descriptor of drug-host interaction, is usually conducted at the later stage of drug 
development.  However, the disposition of the biological active substances in the body 
system determines the success of these substances to become therapeutic agents.  As a 
consequence, the successful rate of bringing chemical entities from preclinical to clinical 
stage was rather low, estimated to be 1/2000 (Nassar-1, Nassar-2, 2004).  The failure in most 
cases is due to the unsatisfactory PK after the chemical entities enter the biological system 
(Fig. 2) (Grossman, 2009).   
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Fig. 1. ADME determines the destination of xenobiotics in biological system.   
 
 
 
 
 
Fig. 2. Integrative pharmacodynamic and pharmacokinetic outcome determines the 
therapeutic efficacy of drugs.   
3. The beauty and odds of xenobiotics in the biological system 
Biological processing of xenobiotics via ADME determines the feasibility of medicinal 
substances to become effective therapeutic agents (Eddershaw et al., 2000; Ekins et al., 2010; 
Lombardo & Waters, 2011; Ruiz-Garcia et al., 2008).  Factors affecting the fate of xenobiotics 
may exist anywhere along the ADME process and may lead to a change of well designed 
and documented pharmacokinetic profiles of registered pharmaceuticals (Harris et al., 2003; 
Yang C. Y. et al., 2006).  Risk and benefit assessment is thus not only on the medicinal 
substances per se, but also on factors affecting the biological processing of these substances.   
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3.1 The sites and the mechanisms of xenobiotic–host Interaction 
Scientific evidences regarding to the sites and mechanisms of xenobiotic–host interaction are 
emerging.  It is well documented that transporters in the intestine, liver, kidney and brain 
are involved in the uptake and the efflux of chemical substances like food and drugs 
(Brandsch et al., 2008; Oostendorp et al., 2009; Rubio-Aliaga & Daniel, 2008; Yang et al., 
2006; Zhou, 2008).  The pharmacological effect and the disposition of drugs are thus highly 
influenced by the function of transporters located in specific tissues (Ayrton & Morgan, 
2008; Calcagno et al., 2007; Türk & Szakács, 2009; Yuan et al., 2008).  Evidence also 
supported the consequence of the involvement of transport proteins in the pharmacokinetic 
variability and the safety of drugs in human use (Tsuji, 2006).   
3.2 Drug-drug and drug-food interaction along biological processing of xenobiotics 
Reports demonstrated that transporters in the intestine for absorption and in the kidney for 
excretion showed characteristics of broad substrate specificity, indicating the possibility of 
drug-drug and drug-food interactions.  The pitfalls of transporter-mediated drug-drug, 
drug-food or drug-herbal interaction is thus an important issue to be elaborated for drug 
safety concern (Huang & Lesko, 2004; Pal & Mitra, 2006; Ward, 2008).  Kidney, for example, 
is one of the important sites of drug-drug and drug-food interaction.  The competition of 
renal transporter between drugs and food may change the bioavailability of drugs due to 
the change of renal clearance rate (Bachmakov et al, 2009; Kindla et al., 2009; Li et al., 2006; 
Tsuda et al., 2009; Wojcikowski, 2004).  Thus a predictable ADME-toxicity modulation is 
important in the process along drug development (Szakács et al., 2008).   
The metabolic system processing the biotransformation of xenobiotics provides another 
pitfalls for drug-drug and drug-food interaction (Tirona & Bailey, 2006).  Reports indicated 
that hepatotoxicity (Brazier & Levine, 2003; Furbee et al., 2006; Holt & Ju, 2006; Schiano, 
2003; Tang, 2007; Wang et al., 2006) and renal toxicity (Wojcikowski et al., 2004) of 
xenobiotics are associated with the formation of reactive metabolites no matter they are 
from synthetic or herbal resources (Venkatakrishnan & Obach, 2007; Zhou et al., 2007).   
3.3 Risk-benefit assessment of pharmaceutical products 
As potential risks in relation to the administration of xenobiotics are frequently reported, the 
biological activity is not the only criteria for the justification of medicinal substances for 
therapeutic use.  The integrative judgment of medicinal substance-host interaction based on 
the quality, safety and efficacy is essential for risk-benefit assessment in drug approval.  In 
order to increase the successful rate, strategy in new drug development is thus evolved from 
the conventional sequential involvement of chemistry, pharmacodynamics (PD), toxicity 
(tox) and pharmacokinetics (ADME/PK) (Fig. 3a) to parallel PD/PK assessment (Fig. 3b) for 
optimizing drug efficacy.  Novel approaches are using biological ADME mechanism for new 
drug design at early stage of drug discovery (Fig. 3c) (Dingemanse & Appel-Dingemanse, 
2007).  Evidence-based justification of drug-drug and drug-food interaction also becomes a 
standard procedure for safety evaluation of new drug application by pharmaceutical 
regulatory bodies (Hartford et al., 2006; Zhang et al., 2008).   
3.4 Pharmacovigilance 
Genetic and culture differences such as food and nutritional intake are among the factors 
that influence the therapeutic outcome of drugs.  Therefore, safety evaluation of marketed 
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Fig. 3. The evolution of strategies in drug development from (a) sequential involvement of 
PD, ADME /PK to (b) PD and ADME /PK abreast and to (c) ADME for new drug design.   
drugs should be based on good quality of evidence of the growing population that take the 
drug after a reasonably long period of time (Laupacis et al, 2002).  In order to overcome the 
fragmentation of information, pharmacovigilance requires comprehensive risk-benefit 
assessment based on the accumulated data of the population using the individual 
pharmaceutical product (McFarlance, 2002).   
4. Potential risk from co-medication 
4.1 Polypharmacy 
Polypharmacy is widespread in the general population, especially in the elderly.  Besides 
registered medicine, the population of CAM users is growing, especially in the aged and in 
patients with chronic disease (Chung et al., 2009; Desai & Grossberg, 2003; Kennedy, 2005; 
McKenna & Killoury, 2010; Miller et al., 2008; Nowack et al., 2009; Ohama et al., 2006; 
Ramage-Morin, 2009).  The most prevalent use of CAM are for treating cardiovascular 
disease, pain healing, cancer adjuvant therapy and obesity (Izzo, 2005).  According to a 
questionnaire-based survey research on CAM use, 55% of the 356 patients registered in 
hospital emergency department have tried at least one CAM therapy within the past 12 
months, 17% have tried CAM for their presenting medical problem (Li et al., 2004).   
A considerable large portion of patients take CAM with registered medicines without 
notification to professionals.  Therefore, standard tools for regular monitoring of 
pharmacovigilance have its limitation.  Safety threat as a result of drug-CAM interaction 
emerges from various scientific and pharmacoepidemiological reports (Anastasi et al., 2011; 
Balbino & Dias, 2010; Chiang et al., 2005; Cockayne et al., 2005; Sim & Levine, 2010; Smith et 
al., 2011; Tarirai et al., 2010).  As it is not evidence-based, risk from polypharmacy especially 
from co-medication of prescribed drugs with CAM is inevitable.  A UK perspective report 
raised an increasing awareness of herbal use and the need to develop pharmacovigilance 
practice (Barnes, 2003).   
4.2 Social aspects in relation to the risk of medication and polypharmacy 
Polypharmacy implies a potential risk of pharmacovigilance in societies where co-
medication is prevalent.  Taiwan for example is known for its outstanding national health 
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insurance program which benefits 99% of the population.  The welfare-like program 
rendered Taiwanese a potential overuse of the healthcare system, as indicated by the high 
physician’s visit per person and the large number of drug items per prescription (Table 1) 
(Department of Health, 2008; Gau, 2007; Huang, & Lai, 2006; Hsu et al., 2004).  Moreover, 
most of the prescriptions are massively dispensed in hospitals, with a released rate of 
0.41%(year 2008) to community pharmacies on refills for patients with chronic disease 
(Bureau of National Health Insurance, Department of Health, 2011). The imbalanced 
distribution of pharmacy service between hospitals, clinics and community pharmacies 
further reflects the lack of mechanism for risk prevention on medication (Table 2).   
 
 Taiwan OECD countries 
physician’s visits (no. of visits/person/year)  15.2 5.9 
Drug items per prescription 4.2 1.9 
Drug expenditure to total national health insurance cost  25% ~15% 
Table 1. Statistics of medication profile in Taiwan.  Data of year 2008 are from National 
Health Insurance Database.   
 
Number of 
prescriptions 
Number of 
pharmacists 
Prescriptions dispensed 
/pharmacist/day 
Medical Center 31,172,000 725 154 
Regional Hospital 34,368,000 880 139 
Local hospital  35,137,000 770 160 
Clinics 217,052,000 8,404 91 
Community Pharmacy 31,290,000 3,348 33 
Table 2. Distribution of prescriptions to pharmacy for dispensing in Taiwan.  Data of year 
2008 are from National Health Insurance Database.   
4.3 Regulatory aspects in relation to the risk of polypharmacy 
CAM are marketed without license in most of the developed countries.  Claims for 
therapeutic efficacy of CAM are thus prohibited or limited to authorized indications (World 
Health Organization, 2001 & 2004; Ziker, 2005).  However, traditional Chinese medicine 
(TCM) are classified as licensed drugs in oriental societies.  For example, TCM are separately 
registered from conventional pharmaceutical products via bilateral regulatory systems in 
Taiwan.  Drug adverse events are managed via bilateral reporting systems as well.  With the 
requirement of good manufacturing practice (GMP), the number of license issued to 
conventional medicine decreased drastically.  The number of TCM license, on the other 
hand, increased with a significantly high growth rate (Table 3).  The separation of regulatory 
and administrative management on conventional medicine and TCM leads to the 
fragmentation of information regarding to polypharmacy.  Patients and consumers are thus 
facing an unknown risk from irrational co-medication.   
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Conventional pharmaceutical 
products 
TCM products 
year prescription 
over-the-
counter 
Prescription 
over-the-
counter 
1995 14718 7152 2394 4663 
Total in 1995 21,870 7,075 
2006 4235 1385 4663 6444 
Total in 2006 5,620 11,107 
Table 3. Licenses issued for conventional pharmaceutical products and TCM in Taiwan.   
4.4 Pharmaco-epidemiological aspects in relation to the risk of polypharmacy 
Herbal medicine includes TCM, CAM and nutraceuticals.  With the prevalence of CAM use, 
inappropriate commercial advertisements in the media are also prevalent.  According to a 
report of survey study in Taiwan, the identified illegal advertisement of products with 
therapeutic claims on cable TV counts for 12% of total healthcare related advertisements 
(183 out of 1591 cases), of which 41% goes to food and nutraceuticals and 15% goes to TCM 
(Fig. 4a).  The illegal advertisement rate is even higher on radio, with TCM ranked the top 
(53%) followed by nutraceuticals (31%) (Fig. 4b).  Most of the advertisements are claims for 
weight reduction and for the treatment of erectile dysfunction while are lack of evidence.   
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Fig. 4. Identified illegal advertisement of medicinal products in year 2004 on cable TV (a) 
and (b) radio in Taiwan (data are from Taiwan Drug Relief Foundation).   
The incidence rate of end-stage renal disease (ESRD) of Taiwan ranked the top among the 
world (Fig. 5) (United States Renal Data System, 2006).  The prevalence rate of ESRD in 
Taiwan raised from 1 per 2999 population in year 1991 to 1 per 498 population in 2006 (Fig. 
6) (National Kidney Foundation, 2006).  Reports indicated that herbal therapy was positively 
associated with chronic kidney disease (Bagnis et al., 2004; Chang et al., 2001; Chang et al., 
2007; Guh et al., 2007; Nowack, 2008; Zhou et al., 2007).  Safety issue in relation to 
polypharmacy becomes a challenge to the authority and the medical society.   
www.intechopen.com
 
System Building for Safe Medication 
 
195 
0 50 100 150 200 250 300 350 400
Russia
Philippines
Iceland
Finland
Australia
Norway
Netherlands
Malaysia
New Zealand
Spain/Castile y Leon
Scotland
Turkey
Sweden
Thailand
Spain/Andalucia
Spain/Basque Ctry
Denmark
Spain/Catalonia
Hungary
Uruguay
Canada
Croatia
Chile
Spain/Valencia
Austria
Italy
Czech Republic
Rep. of Korea
Luxembourg
Belgium, Dutch speaking
Belgium, French speaking
Israel
Germany
Greece
Japan
Taiwan
United States
Jalisco (Mexico)
C
o
u
n
tr
y
Incidence Rate (per million population)
 
Fig. 5. The statistics of global incidence rate of end-stage renal disease (ESRD).   
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Fig. 6. The prevalence of end stage renal dialysis (ESRD) in Taiwan.  Data are from the 
Bureau of National Health Insurance, Department of Health.   
5. Risk management of medication 
5.1 Global trend on risk management of pharmaceutical products  
Two conceptual aspects regarding to risk management on medication were introduced by 
International Conference on Harmonization (ICH) (Bahri & Tsintis, 2005; Moseley, 2004; 
Tsintis & La Mache, 2004).  Pharmacovigilance Specification (PV) addressed the evidence-
based justification of drug safety throughout the life cycle of individual pharmaceutical 
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product from preclinical development to post-market use.  Pharmacovigilance Planning 
(PVP) emphasizes risk prevention and minimization of medication use (Callre ́us, T. 2006; 
Cappe et al., 2006).   
5.2 From pharmacovigilance to pharmacovigilance planning 
Following the conceptual initiation of PVP, the Council for International Organizations of 
Medical Sciences (CIOMS) and ICH developed and published Topic ICH E2E Guidance in 
2005 as an action to implement PVP (International Conference on Harmonization, 2005).  
The guidance addresses the identification of all possible signals of risk regarding to drug 
use.  Evidence-based approaches to risk assessment, such as genetic/racial and cultural 
factors (food and nutrition), are included.  Pharmaco-epidemiological study becomes 
important for risk analysis (Fig. 7).   
 
 
Fig. 7. The evolution of risk management of medication from product-oriented 
pharmacovigilance to risk management in pharmacovigilance planning.   
5.3 System building for safe medication 
The change from PV to PVP indicated the evolution from product-oriented risk 
management on individual medicine to a proactive risk prevention and minimization of 
medication.  However, the risk management for pharmacovigilance initiated by ICH is 
essentially based on the refinement of safety-signal identification of registered 
pharmaceutical products.  What is less addressed is the medicinal-type products without 
drug license.  Risk prevention and minimization is thus difficult to be implemented in 
societies where patients tend to take conventional medicine and CAM without evidence-
based justification in mind.   
There is urgent need to call for public attention for the system building of safe medication.  
Risk and benefit assessment should be conducted on subjects who take all kinds of 
medicinal products via an un-biased integrative justification process.  Humanity-based 
medication thus should be justified by the quality, safety and efficacy of medicines, no 
matter they are from synthetic, biological, biotechnological or herbal resources.   
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5.4 GDDP is essential for implementing pharmacovigilance planning 
Following the guideline of Good Dispensing Practice (GDP), safe medication is 
fundamentally guaranteed for patients taking licensed pharmaceutical products.  However, 
besides professional pharmacists, stakeholders involved in product and information 
delivery, namely product providers, medical professionals, the third party drug payers, 
media, patients and consumers, and policy makers in charge of food and drug 
administration, should also be responsible for the system building of safe medication.  The 
concept of Good Dispensing and Delivery Practice (GDDP) is thus proposed.  In this aspect, 
good practice in the delivery of medicinal products as well as medication information is 
equally important to good dispensing practice (Fig. 8).  This is especially important in 
societies where the due process of safe medication is not properly implemented by the 
authority.  For example, due to the lack of a due process in the separation of prescription 
from dispensing in Taiwan, irrational co-medication is common.  A study on risk factor 
analysis of co-medication of cisapride and erythromycin identified that the major risk came 
from the mal-prescription of medical professionals (Gau et al., 2007).   
 
 
Good Dispensing and Delivery Practice
pharmacist
medical professionals
authority: policy for due process
third party: insurance payer / pricing policy
industry: marketing with corporation social responsibility
media: social responsibility
consumers: risk management of self-medication
medicinal products
registered medicine
 
 
Fig. 8. Good Dispensing and Delivery Practice is essential for the system building of safe 
medication.   
6. Conclusion 
Risk of medication not only comes from registered drugs but also from irrational use and co-
use of all types of products claiming therapeutic effect.  Evidence-based medication is thus 
important for the system building of safe medication.  The use of medicinal products needs 
to be evolved from pharmacovigilance of individual products to humanity-based integrative 
risk-benefit assessment for risk minimization.  Although challenging the culture in societies 
prevalent of irrational medication and co-medication is most likely unwelcome, mechanism 
for consumer protection on system building for risk minimization need to be continuously 
addressed, proactively designed and pragmatically implemented.   
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